Senti Biosciences (NASDAQ:SNTI) Stock Rating Lowered by Wall Street Zen

Senti Biosciences (NASDAQ:SNTI) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other equities research analysts have also recently weighed in on the stock. Chardan Capital restated a “buy” rating and issued a $12.00 price objective on shares of Senti Biosciences in a research report on Friday, August 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a report on Wednesday, October 8th. Finally, HC Wainwright began coverage on Senti Biosciences in a research report on Tuesday, October 14th. They issued a “buy” rating and a $12.00 price objective on the stock. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.67.

Senti Biosciences Trading Up 7.7%

NASDAQ:SNTI opened at $1.95 on Friday. The stock has a market capitalization of $51.01 million, a P/E ratio of -0.22 and a beta of 2.09. Senti Biosciences has a 1 year low of $1.26 and a 1 year high of $16.94. The firm has a 50 day moving average of $1.69 and a 200-day moving average of $2.20.

Senti Biosciences (NASDAQ:SNTI) last announced its earnings results on Thursday, August 7th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.02. The business had revenue of $0.50 million during the quarter, compared to analyst estimates of $1.30 million. As a group, analysts forecast that Senti Biosciences will post -14.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SNTI. Geode Capital Management LLC grew its stake in shares of Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after purchasing an additional 117,588 shares during the period. Armistice Capital LLC bought a new position in Senti Biosciences during the second quarter worth about $1,883,000. Heights Capital Management Inc. acquired a new position in shares of Senti Biosciences during the 1st quarter worth about $2,520,000. Finally, Nantahala Capital Management LLC bought a new stake in shares of Senti Biosciences in the 1st quarter valued at about $2,984,000. 25.70% of the stock is currently owned by institutional investors.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.